Loteprednol etabonate

Names

[ CAS No. ]:
82034-46-6

[ Name ]:
Loteprednol etabonate

[Synonym ]:
Androsta-1,4-diene-17-carboxylic acid, 17-((ethoxycarbonyl)oxy)-11-hydroxy-3-oxo-, chloromethyl ester, (11β,17α)-
chloromethyl (8S,9S,10R,11S,13S,14S,17R)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthrene-17-carboxylate
(8S,9S,10R,11S,13S,14S,17R)-17-[(éthoxycarbonyl)oxy]-11-hydroxy-10,13-diméthyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodécahydro-3H-cyclopenta[a]phénanthrène-17-carboxylate de chlorométhyle
Chloromethyl 17a-ethoxycarbonyloxy-11b-hydroxyandrosta-1,4-diene-3-one-17b-carboxylate
(11b,17a)-17-[(Ethoxycarbonyl)oxy]-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylic Acid Chloromethyl Ester
Loteprednol (INN)
Androsta-1,4-diene-17-carboxylic acid, 17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxo-, chloromethyl ester, (11β,17α)-
Loteprednolum
Loteprednol Etabonate
17a-Ethoxycarbonyloxy-D'-cortienic Acid Chloromethyl Ester
Loteprednol [INN:BAN]
Chloromethyl (11β,17α)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-3-oxoandrosta-1,4-diene-17-carboxylate
HGP 1
loteprednol
Chlormethyl-(8S,9S,10R,11S,13S,14S,17R)-17-[(ethoxycarbonyl)oxy]-11-hydroxy-10,13-dimethyl-3-oxo-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-17-carboxylat

Biological Activity

[Description]:

Loteprednol Etabonate is an anti-inflammatory corticosteroid used in optometry and ophthalmology.IC50 Value:Target: Glucocorticoid Receptorin vitro:in vivo: Intravenous administration of loteprednol etabonate (5 mg/kg) to dogs revealed a terminal half-life of 2.8 h, a volume of distribution of 3.7 L/kg, and a total body clearance of 0.9 L/h/kg. Intact loteprednol etabonate was not detectable in the urine. After oral administration of the drug (5 mg/kg) to dogs, only metabolites, but no intact drug, were found in the plasma, an indication for a high first-pass effect. A pronounced binding of the drug to plasma protein (> 90%) and a high erythrocyte-buffer partition coefficient of 7.8 were determined in vitro.

[Related Catalog]:

Signaling Pathways >> GPCR/G Protein >> Glucocorticoid Receptor

Research Areas >> Inflammation/Immunology

Natural Products >> Others

[References]

[1]. Noble S, Goa KL. Loteprednol etabonate: clinical potential in the management of ocular inflammation. BioDrugs. 1998 Oct;10(4):329-39.

[2]. Szelenyi I, Hochhaus G, Heer S et al. Loteprednol etabonate: a soft steroid for the treatment of allergic diseases of the airways. Drugs Today (Barc). 2000 May;36(5):313-20.

[3]. Howes JF. Loteprednol etabonate: a review of ophthalmic clinical studies. Pharmazie. 2000 Mar;55(3):178-83.

[4]. Pavesio CE, Decory HH. Treatment of ocular inflammatory conditions with loteprednol etabonate. Br J Ophthalmol. 2008 Apr;92(4):455-9.

[5]. Comstock TL, Decory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623.

[6]. Loteprednol

[Related Small Molecules]

Chemical & Physical Properties

[ Density]:
1.3±0.1 g/cm3

[ Boiling Point ]:
600.1±55.0 °C at 760 mmHg

[ Melting Point ]:
220.5-223.5ºC

[ Molecular Formula ]:
C₂₄H₃₁ClO₇

[ Molecular Weight ]:
466.952

[ Flash Point ]:
316.7±31.5 °C

[ Exact Mass ]:
466.175842

[ PSA ]:
99.13000

[ LogP ]:
3.17

[ Appearance of Characters ]:
white to beige

[ Vapour Pressure ]:
0.0±3.9 mmHg at 25°C

[ Index of Refraction ]:
1.571

[ Storage condition ]:
-20°C Freezer

[ Water Solubility ]:
DMSO: soluble5mg/mL, clear (warmed)

MSDS

Click to get detail MSDS

Safety Information

[ Hazard Codes ]:
Xi

[ RIDADR ]:
NONH for all modes of transport

[ HS Code ]:
2937229000

Customs

[ HS Code ]: 2937229000

Articles

Topical cyclosporine a 1% for the treatment of chronic ocular surface inflammation.

Eye Contact Lens 40(5) , 283-8, (2014)

To evaluate the use of topical cyclosporine A (CsA) 1% emulsion in the treatment of chronic ocular surface inflammation (OSI).We conducted a retrospective chart review of patients with various forms o...

Small-incision lenticule extraction for myopia: results of a 12-month prospective study.

Optom. Vis. Sci. 92(1) , 123-31, (2015)

To analyze the safety, efficacy, stability, and predictability of small-incision lenticule extraction to correct myopia.Patients were evaluated preoperatively and then at 1 day, at 2 weeks, and at 1, ...

Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery.

J. Cataract Refract. Surg. 39(2) , 168-73, (2013)

To evaluate the efficacy of loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the control of postoperative inflammation in patients having routine cataract surgery.Private practice, Stil...